QIAGEN Acquires Additional Licenses From Roche, Idaho Technology

QIAGEN has acquired additional licenses from Roche and Idaho Technology related to the use of instrumentation and reagents for PCR-based molecular testing.

Reportedly, the agreements cover thermal cycler rights and real-time polymerase chain reaction (PCR) methods for diagnostics and all other applications. In addition, the agreements also cover rights for high resolution melting curve analysis (HRM) technology.

With these agreements QIAGEN will have full freedom to offer HRM related instruments and reagents under license in all formats and for all purposes in research and diagnostics worldwide.

The company also announced that it has already launched and is currently releasing new HRM products capitalising on the complete license portfolio as well as QIAGEN’s own intellectual property, including a range of HRM PCR Kits and a new software solution for HRM based genotyping.

Moreover, QIAGEN is preparing submissions of the Rotor-Gene Q and related sample and assay technologies for regulatory approval in both the US and Europe.

Achim Ribbe, executive director of business development at QIAGEN, said: “This additional IP portfolio enables us to develop and market PCR solutions based on of the most advanced technologies for molecular diagnostics. HRM allows additional differentiation for genotyping and can be extremely well leveraged on our Rotor-Gene Q HRM instrument.

“We now have a PCR intellectual property puts us in the position to offer our customers in molecular diagnostics, pharma, applied testing and life science research.”